A summary of the clinical status of asparaginase.
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002908:Chronic Disease; D004357:Drug Synergism; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D013997:Time Factors
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D001215:Asparaginase